Tejas Patil (@TejasPatilMD) ranks #48 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 4 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: FLAURA2, REZILIENT3, CROWN. CMS Open Payments lists $29,556 in 2025 general payments.
At a Glance
- 16 posts naming a trial in 2026
- 17 trials discussed by name
- Lung Cancer: US #48 · 4 physicians engaged
- CMS Open Payments lists $29,556 in 2025 general payments.
This Month
What Tejas Patil has posted in the last 30 days. Updated November 10, 2026.
⭐️ctDNA dynamics in #EGFR and #ALK NSCLC will be addressed in these two publications. 1⃣FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem) 2⃣Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study Beyond addressing the obvious (ctDNA positivity is bad, TP53 mutations confer worse outcomes), I'm really looking for how these data position integration of ctDNA into trial design. For CROWN, can these results inform the initial 20% drop within first 6 months seen within lorlatinib arm of CROWN survival curve? @lcsmchat @OncoAlert @OncLive @Onco_Nexus @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchHQ @EGFRResisters @ALKPositiveinc @ALKpositiveINT @YoungLungCancer
🌟AND finally, #ESMO26 wouldn't be complete without some of the HEAVY hitters. I expect these data to change practice! 1⃣Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial. I fully expect this trial to establish DLL3 TCE as the dominant first line strategy in SCLC and will likely be practice changing. 2⃣Krascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC. Given the evolution of KRAS G12Ci in this space, what is notable here is the direct prospective comparison to current KRAS G12Ci (adagrasib / sotorasib). Looking forward to ascertain magnitude of potential benefit and safety differences. 3⃣INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Technically not a lung cancer study, but I believe this trial to be game-changing from a proof-of-concept approach. In my mind, this study establishes personalized mRNA-based approaches as a viable approach and worthy of research and clinical investment. @lcsmchat @OncoAlert @OncLive @Onco_Nexus @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchHQ @KRASKickers @SclcSMASHERS @YoungLungCancer
⭐️How do we improve outcomes for #lungcancer patients with PDL1 < 1% in the 1L setting? This may be addressed with the following two approaches 1⃣Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1-negative advanced non-squamous (nsq) NSCLC: Randomized phase 3 OptiTROP-Lung06 study 2⃣First-line (1L) olomorasib + chemoimmunotherapy (chemo-IO) in KRAS G12C-mutant NSCLC: Updated results from the LOXO-RAS-20001 and SUNRAY-01 trials. These are separate strategies (ADC vs TKI), but both address a fundamental need which is combination approaches for certain subsets of 1L NSCLC. @lcsmchat @OncoAlert @OncLive @Onco_Nexus @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchHQ @YoungLungCancer @KRASKickers
⭐️Optimal integration and duration of pembrolizumab will be evaluated in two critical studies that I believe address very practical concerns for thoracic oncologists. 1⃣PERSEE phase 3 trial (GFPC 01-2020) - will address the value of pembrolizumab in PD-L1 ≥50% 2⃣IFCT-2103 DIAL phase 2-3 randomized trial - will address value of continuing maintenance pem/pembro beyond 2 yrs in a prospective fashion. @lcsmchat @OncoAlert @OncLive @Onco_Nexus @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchHQ @YoungLungCancer
Who Amplifies Tejas Patil
Physicians who reposted Tejas Patil’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #48 | — | 4 | 5 | Full ranking |
What Colleagues Are Saying About Tejas Patil
2026 posts by fellow physicians that mention @TejasPatilMD, quoted word for word.
Join us September 23 10am EDT as we discuss impactful studies from #WCLC26! Looking foward to hearing from thoracic oncology experts & friends: Drs. @SuyogCancer @SewantiLimaye @LauraAlderMD @g_mountzios @TejasPatilMD @ChandrakanthMv Free registration: https://t.co/odIHUm2lLY https://t.co/khZolqgkdI
A huge thank you to our incredible faculty @StephenVLiu @LauraAlderMD @TejasPatilMD @g_mountzios @ullas_batra Dr Chandrakanth, Dr Karan Sood for an outstanding #OncoWisdom discussion on What’s New in Lung Cancer from WCLC 2026. 🙏 402 registrations | 160 attendees Grateful for the time, expertise and honest discussion 🙂. Thank you for making it special! 🙏 And thank you for all those who attended it . I hope it was useful for all of you 🙂
Trials Tejas Patil Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| FLAURA2 | 2 | #14 of 25 | Oct 24, 2026 |
| REZILIENT3 | 2 | #17 of 27 | Sep 14, 2026 |
| CROWN | 1 | #35 of 36 | Oct 24, 2026 |
| DeLLphi-305 | 1 | #73 of 86 | Oct 24, 2026 |
| KRASCENDO-1 | 1 | #38 of 49 | Oct 24, 2026 |
| OptiTROP-Lung06 | 1 | #24 of 29 | Oct 24, 2026 |
| PERSEE (GFPC 01-2020) | 1 | #30 of 34 | Oct 24, 2026 |
| PAPILLON | 1 | #25 of 26 | Oct 7, 2026 |
| MAVERICK (SWOG S1827) | 1 | #27 of 33 | Sep 11, 2026 |
| HARMONi-2 | 1 | #13 of 19 | Sep 11, 2026 |
| HARMONi-6 | 1 | #64 of 74 | Sep 11, 2026 |
| HARMONi | 1 | #7 of 16 | Sep 11, 2026 |
| MDT-BRIDGE | 1 | #13 of 18 | Sep 11, 2026 |
| ARROS-1 | 1 | #21 of 26 | Sep 11, 2026 |
| NAUTIKA1 (KRAS G12C) | 1 | #7 of 8 | Sep 11, 2026 |
| IMforte | 1 | #12 of 12 | Jul 12, 2026 |
| DeLLphi-304 | 1 | #14 of 23 | May 26, 2026 |
Tejas Patil on FLAURA2
⭐️ctDNA dynamics in #EGFR and #ALK NSCLC will be addressed in these two publications. 1⃣FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem) 2⃣Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study Beyond addressing the obvious (ctDNA positivity is bad, TP53 mutations confer worse outcomes), I'm really looking for how these data position integration of ctDNA into trial design. For CROWN, can these results inform the initial 20% drop within first 6 months seen within lorlatinib arm of CROWN survival curve? @lcsmchat @OncoAlert @OncLive @Onco_Nexus @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchHQ @EGFRResisters @ALKPositiveinc @ALKpositiveINT @YoungLungCancer
@SuyogCancer I think you will need chemotherapy, given FLAURA2 and PAPILLON. Same principles apply. I also worry about CNS coverage with sunvozertinib monotherapy.
Tejas Patil on REZILIENT3
🤔The myelosuppression in REZILIENT3 is strange. This is the same platinum pemetrexed chemotherapy used in PAPILLION and FLAURA-2, but with way higher adverse event profile. 1⃣ There is a high rate of Gr≥3 cytopenias in first 4 cycles within the experimental arm. This is unusual and not what I would have predicted about the zipalertinib + platinum combo. I still don't have a great theory for why this is the case. 2⃣ The most common reason drug discontinued in experimental arm was still pemetrexed (31.4%), though common reasons for discontinuation in my practice (fatigue, renal toxicity) were not listed as common AEs. 3⃣ Zipalertinib had an 80% dose reduction rate and a 17% discontinuation rate, likely related to EGFR mediated side effects (rash, paronychia). I suspect these were chronic Gr2 AEs, which is important as we think about how long term use of zipalertinib affects patient's QoL. @EGFRResisters @EgfrUk @Exon20Group @YoungLungCancer
4. REZILIENT 3 🤓 Permit me to nerd out for a bit. Why are #EGFR Exon 20 insertions so hard to target? On a high level, there are TWO reasons. 1⃣Steric hinderance: #EGFR Exon 20 insertions disrupt the drug-binding pocket, with a shift ofthe αC-helix into the pocket owing to the C-terminal insertions. 2⃣Preserved ATP affinity (main reason): In contrast to sensitizing #EGFR mutations (exon 19 del, L858R, L861Q), ex20ins can INCREASE ATP affinity. This creates a pharmacologic problem because the TKI must compete with abundant intracellular ATP. 📋 The PAPILLION trial showed a PFS advantage with ami+chemo vs chemo alone (HR 0.40). REZILIENT-3 may build on this and potentially show that a zipalertinib+chemo > chemo alone. ❓Questions (if trial is positive): When should we use ami+chemo over zipalertinib+chemo? What is CNS efficacy? How does the HR benefit here stack up against sunvozertinib? SOURCES 👉🏽https://t.co/o2ArNSPS68 👉🏽https://t.co/dUCJIPglGY 👉🏽https://t.co/3cIkbcceIV [GREAT review article on EGFR and HER2 biology] @EGFRResisters @EgfrUk @Exon20Group @EGFRSummit @lcsmchat @OncoAlert @OncLive @Onco_Nexus @OncogeneCancer @Lung_Cancers @LungCancerEu @YoungLungCancer
Tejas Patil on CROWN
⭐️ctDNA dynamics in #EGFR and #ALK NSCLC will be addressed in these two publications. 1⃣FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem) 2⃣Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study Beyond addressing the obvious (ctDNA positivity is bad, TP53 mutations confer worse outcomes), I'm really looking for how these data position integration of ctDNA into trial design. For CROWN, can these results inform the initial 20% drop within first 6 months seen within lorlatinib arm of CROWN survival curve? @lcsmchat @OncoAlert @OncLive @Onco_Nexus @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchHQ @EGFRResisters @ALKPositiveinc @ALKpositiveINT @YoungLungCancer
Tejas Patil on DeLLphi-305
🌟AND finally, #ESMO26 wouldn't be complete without some of the HEAVY hitters. I expect these data to change practice! 1⃣Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial. I fully expect this trial to establish DLL3 TCE as the dominant first line strategy in SCLC and will likely be practice changing. 2⃣Krascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC. Given the evolution of KRAS G12Ci in this space, what is notable here is the direct prospective comparison to current KRAS G12Ci (adagrasib / sotorasib). Looking forward to ascertain magnitude of potential benefit and safety differences. 3⃣INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Technically not a lung cancer study, but I believe this trial to be game-changing from a proof-of-concept approach. In my mind, this study establishes personalized mRNA-based approaches as a viable approach and worthy of research and clinical investment. @lcsmchat @OncoAlert @OncLive @Onco_Nexus @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchHQ @KRASKickers @SclcSMASHERS @YoungLungCancer
Tejas Patil on KRASCENDO-1
🌟AND finally, #ESMO26 wouldn't be complete without some of the HEAVY hitters. I expect these data to change practice! 1⃣Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial. I fully expect this trial to establish DLL3 TCE as the dominant first line strategy in SCLC and will likely be practice changing. 2⃣Krascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC. Given the evolution of KRAS G12Ci in this space, what is notable here is the direct prospective comparison to current KRAS G12Ci (adagrasib / sotorasib). Looking forward to ascertain magnitude of potential benefit and safety differences. 3⃣INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Technically not a lung cancer study, but I believe this trial to be game-changing from a proof-of-concept approach. In my mind, this study establishes personalized mRNA-based approaches as a viable approach and worthy of research and clinical investment. @lcsmchat @OncoAlert @OncLive @Onco_Nexus @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchHQ @KRASKickers @SclcSMASHERS @YoungLungCancer
Tejas Patil on OptiTROP-Lung06
⭐️How do we improve outcomes for #lungcancer patients with PDL1 < 1% in the 1L setting? This may be addressed with the following two approaches 1⃣Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1-negative advanced non-squamous (nsq) NSCLC: Randomized phase 3 OptiTROP-Lung06 study 2⃣First-line (1L) olomorasib + chemoimmunotherapy (chemo-IO) in KRAS G12C-mutant NSCLC: Updated results from the LOXO-RAS-20001 and SUNRAY-01 trials. These are separate strategies (ADC vs TKI), but both address a fundamental need which is combination approaches for certain subsets of 1L NSCLC. @lcsmchat @OncoAlert @OncLive @Onco_Nexus @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchHQ @YoungLungCancer @KRASKickers
Tejas Patil on PERSEE (GFPC 01-2020)
⭐️Optimal integration and duration of pembrolizumab will be evaluated in two critical studies that I believe address very practical concerns for thoracic oncologists. 1⃣PERSEE phase 3 trial (GFPC 01-2020) - will address the value of pembrolizumab in PD-L1 ≥50% 2⃣IFCT-2103 DIAL phase 2-3 randomized trial - will address value of continuing maintenance pem/pembro beyond 2 yrs in a prospective fashion. @lcsmchat @OncoAlert @OncLive @Onco_Nexus @LungCancerEu @Lung_Cancers @LungCancerRx @MedwatchHQ @YoungLungCancer
Tejas Patil on PAPILLON
This press release, coupled with PAPILLON and REZLIENT3, tell me that upfront platinum chemo is an important part of the treatment strategy for #Egfr Exon 20 NSCLC. @Exon20Group @EGFRResisters @EgfrUk @EGFRSummit @OncoAlert @Lung_Cancers @YoungLungCancer https://t.co/WtPqeaXTRQ
Tejas Patil’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
👏🏽 ELEGANT paper on mechanisms of resistance to tricomplex RAS inhibitors (eg, daraxonrasib) published in @CellCellPress! THREE major pathways observed: 1⃣ RAS Y64 mutations (weaken daraxonrasib indole ring with weaker KRAS tricomplex formation) 2⃣ RAS Y71 mutations (allosteric effect ▶️native RAS-RAF interaction favored over tri-complex) 3⃣ Class III BRAF mutants (RAF dimerization repositions cysteine-rich domain ▶️ intensifies native KRAS binding ▶️ harder for tricomplexes to displace A MAIN insight [for me] is that cancer cells, when faced with intense selection pressures from potent targeted therapies, will often take the path of LEAST resistance! ⭐️Authors show [Figure 1] that there is virtually NO bypass signaling through ERBB or MET family. ⭐️Almost ALL resistance is mediated through alterations in native MAPK pathways, which makes sense (path of least resistance) EXCELLENT one to bookmark and return to: 👉🏽 https://t.co/WaqceNZ6ML @lcsmchat @OncoAlert @KRASKickers @OncogeneCancer @OncLive @Lung_Cancers @MedwatchKate @YoungLungCancer
🎉🔥Use this for #WCLC26 @IASLC Makes job of sorting through abstracts and data MUCH easier! @lcsmchat @OncoAlert @OncLive @Onco_Nexus @MedwatchHQ @Lung_Cancers @LungCancerEu @OncogeneCancer @YoungLungCancer https://t.co/GhFreWgKUz
⭐️ABSTRACT 8516: TSN1611 (Oral KRAS G12D inhibitor) 1⃣KRAS G12D may finally be entering its targeted therapy era. Early phase data for TSN1611 (#ASCO2026) showed encouraging activity across KRAS G12D+ solid tumors. 2⃣Notable signals: - NSCLC: ORR 42.9% (3/7 PR), DCR 100% - PDAC (1-2 prior lines): ORR 36.4%, DCR 72.7% 3⃣Importantly, no DLTs and no MTDs reached. Grade 1-2 GI toxicities despite doses up to 1200 mg BID. To me, suggests allele-specific KRAS G12Di may have a cleaner tox profile relative to pan-RAS approaches. 📋KEY POINT: Oral KRAS G12Di represent a new class of drugs for a patient population that has historically had poor responses to ICI [image below]. Importantly, tox profile looks quite distinct from pan-Ras inhibitors. 🔍If interested in a deeper dive exploring relationship between KRAS G12D and ICI efficacy, bookmark and read paper below! (5/13) 🔗https://t.co/VP37jEqJOF] @lcsmchat @OncoAlert @OncLive @Lung_Cancers @Onco_Nexus @LungCancerRx @KRASKickers
⭐️HONORABLE MENTIONS I wanted to give a spotlight to these abstracts at #ASCO26 that I think warrant a look and additional attention. 1⃣ABSTRACT 8011: LuSato-1 Phase 1 study of radioligand Lu-SSO110 - Radioligands are unique class of drugs and this is a small Ph1 study looking at this class in #SCLC. Early data, but may be play role with sequencing of this class of drugs as the main question. 2⃣ABSTRACT 8014: Transcriptomic analyses of molecular subsets from IMForte predicting who may be respond to lurbinectidin - While I suspect the field will be moving more and more to DLL3 TCE, there are a subset of patients with #SCLC who do benefit from lurbinectidin. This transcriptomic analysis may provide some hypothesis generating insights. 3⃣ABSTRACT 8500: WU-KONG28. - Sunvozertinib monotherapy vs platinum chemotherapy as 1L treatment for EGFR Exon 20 NSCLC. First study looking at an #EGFR #TKI in this space. I'll note that supply chain issues for sunvozertinib still abound in the US. 4⃣ABSTRACT 8082: Prophylactic toclizumab to mitigate CRS. -This is a very cool idea. We are increasingly learning across BiTE platforms that pre-emptive IL-6 blockade may improve tolerability without clearly impairing efficacy. There are limitations with this small dataset (retrospective, non-randomized; only 3 pts in the non-prophylaxis comparator arm, etc etc), but a very important idea worth of prospective study. 🙏🏽🥂🎗️IF YOU MADE IT THIS FAR, THANK YOU! @lcsmchat @OncoAlert @OncLive @OncogeneCancer @Onco_Nexus @Lung_Cancers @LungCancerEu @lcrf_org @LungCancerRx @ALKpositiveINT @ALKPositiveinc @EGFRResisters @EgfrUk @EGFRResisters @Exon20Group @KRASKickers @metcrusaders @ros1cancer @MedwatchKate @YoungLungCancer
⭐️ABSTRACT 8017: Clinical validity of ultrasensitive ctDNA for early stage NSCLC 1⃣ One of the most fascinating ctDNA abstracts from #ASCO2026: with ultrasensitive personalized MRD testing in TRACERx, ctDNA levels ≤ 10 PPM still carried major prognostic significance in resected NSCLC. 2⃣Even “single-digit PPM” ctDNA positivity predicted worse outcomes: - Pre-op: RFS HR 3.25, OS HR 3.49 - Post-op landmark: RFS HR 3.49, OS HR 2.58 3⃣Importantly, ctDNA levels ≥ 10 PPM in stage I patients (who would not get adjuvant therapy) was associated with inferior outcomes. To me, this is an important subgroup, because defining the "high risk stage I patient" who may benefit from adjuvant therapies has been elusive to date. 📋KEY POINT: We should (and I do expect) to see ctDNA increasingly used to define high risk early stage sub-groups. (3/13) @lcsmchat @OncoAlert @OncLive @Lung_Cancers @Onco_Nexus @LungCancerRx @LungCancerEu @MedwatchKate
Industry Payments
CMS Open Payments · 2025 general payments
$29,556 across 27 payments